(Q46690497)

24 December 2017

title

The efficacy of glatiramer acetate in beta-interferon-intolerant MS patients (English)

1 reference

24 December 2017

author name string

Vallittu AM

1

1 reference

24 December 2017

Peltoniemi J

2

1 reference

24 December 2017

Elovaara I

3

1 reference

24 December 2017

Kuusisto H

4

1 reference

24 December 2017

Färkkilä M

5

1 reference

24 December 2017

Multanen J

6

1 reference

24 December 2017

Erälinna JP

7

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 October 2005

1 reference

24 December 2017

Acta Neurologica Scandinavica

published in

1 reference

24 December 2017

volume

112

1 reference

24 December 2017

issue

4

1 reference

24 December 2017

page(s)

234-237

1 reference

24 December 2017

Glatiramer acetate (Copaxone®) therapy for multiple sclerosis

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2005.00464.X

Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2005.00464.X

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2005.00464.X

Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2005.00464.X

Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2005.00464.X

Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2005.00464.X

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2005.00464.X

Lack of evidence for use of glatiramer acetate in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2005.00464.X

Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2005.00464.X

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2005.00464.X

10.1111/J.1600-0404.2005.00464.X

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

PubMed ID

16146492

1 reference

24 December 2017